中信证券股份有限公司 关于益方生物科技（上海）股份有限公司 2024 年度持续督导工作现场检查报告 根据《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，中信证券股份有限公司（以下简称"中信证券"或"保荐 人"）作为正在对益方生物科技（上海）股份有限公司（以下简称"益方生物" "公司""上市公司"）进行持续督导工作的保荐人，对 2024 年度（以下简称"本 持续督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报 告如下： 一、本次现场检查的基本情况 （一）保荐人 中信证券股份有限公司 （二）保荐代表人 杨沁、龚洁 （三）现场检查人员 杨沁、周增骏、黄中一 （四）现场检查时间 2025 年 4 月 11 日、2025 年 4 月 16 日至 18 日、2025 年 5 月 15 日 （五）现场检查内容 现场检查人员对本持续督导期内发行人公司治理和内部控制情况、信息披露 情况、公司的独立性以及与控股股东、实际控制人及其他关联方资金往来情况、 募集资金使用情况、关联交易、对外担保、重大对外投资情况、经营状况等方面 进行了现场检查，具体检查内容详见本报告"二、本次 ...

中信证券股份有限公司 关于益方生物科技（上海）股份有限公司 2024 年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为益方生 物科技（上海）股份有限公司（以下简称"益方生物"或"公司"或"上市公司"） 首次公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理 办法》《上海证券交易所科创板股票上市规则》等相关规定，中信证券履行持续 督导职责，并出具本持续督导年度跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2025 年 4 月 11 日、2025 年 4 月 16 日至 18 日、2025 年 5 月 15 日对公司进行了现场检查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； （2）查阅公司财 ...

5月20日益方生物（688382）收盘价23.46元，收盘上涨15.62%，全天换手率5.34%，振幅13.17%，成交 额4.76亿元。科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。 | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 沪股通专用 | 4935.43 | | 机构专用 | 4244.64 | | 机构专用 | 3808.18 | | 机构专用 | 2198.97 | | 机构专用 | 1992.04 | | 卖出营业部名称 | 卖出金额(万元) | | 中国国际金融股份有限公司上海分公司 | 4549.00 | | 沪股通专用 | 4542.00 | | 兴业证券股份有限公司上海分公司 | 1600.85 | | 机构专用 | 1283.68 | | 机构专用 | 1222.04 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交3.04亿元， 其中，买入成交额为1.72亿 元，卖出成交额为1.32亿元，合计净买入3981.70万元。具体来看，卖出营业部 ...

A股今日（5月20日）全线上扬，市场整体活跃，成交量有所放大；港股亦走高，两大股指均涨超 1%。 中信证券表示，海外订单稳健增长、鸡肉成本下行、人民币贬值、国产宠粮自主品牌整体增长提速、国货 龙头盈利能力持续提升等背景下，2024年、2025年一季度宠物板块业绩持续新高。展望后续，预计海外 需求稳健，国内市场国货替代持续，2025年宠物板块业绩有望持续增长。宠物经济是稀缺赛道，需求韧 性强，国内市场目前仍处"大行业、小龙头"阶段，龙头集中程度有望进一步提升，看好龙头通过产品创 新、品牌和渠道建设不断提升市场份额。 具体来看，A股三大股指盘中发力拉升，创业板指一度涨超1%。截至收盘，沪指涨0.38%报3380.48 点，深证成指涨0.77%报10249.17点，创业板指涨0.77%报2048.46点，北证50指数涨1.22%，沪深北 三市合计成交12114亿元，较昨日（5月19日）增加923亿元。 场 内 超 3800 股 飘 红 ， 宠 物 经 济 概 念 爆 发 ， 天 元 宠 物 （ 301335 ） 20% 涨 停 创 出 新 高 ， 路 斯 股 份 （832419）一度涨停亦创新高；合成生物概念再度活 ...

东海证券指出，我国创新药具备研发成本低、效率高的优点，或成为BD交易首选，中国有望成为低成本研发与生产中心，加速从"仿制跟随"向"创新主 导"转型。大型跨国药企在更严格的定价体系下可能积极寻求降低研发生产成本的路径，我国CXO产业链或将进一步巩固市场地位。仿制药方面，美国仿制 药市场因价格压缩可能引发生产商退出，导致供应短缺，我国具备ANDA批件积累的仿制药企业有望抢占市场份额。建议关注创新药链、器械设备、中药、 医疗服务、连锁药店等细分板块及个股的投资机会。 科创综指ETF华夏紧密跟踪上证科创板综合指数，上证科创板综合指数由上海证券交易所符合条件的科创板上市公司证券组成指数样本，并将样本分红计入 指数收益，反映上海证券交易所科创板上市公司证券在计入分红收益后的整体表现。 科创综指ETF华夏(589000)，场外联接(华夏上证科创板综合ETF联接A：023719；华夏上证科创板综合ETF联接C：023720)。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 截至2025年5月20日 14:24，上证科创板综合指数(000680)上涨0.57%，成分股三生国健(688336)上涨19. ...

Policy Developments - The National Health Commission will enhance investment guarantees for childcare services, aiming for significant improvements in service quality by the end of 2027, including better management systems and increased registration rates for childcare institutions [2] Drug and Device Approvals - Bristol-Myers Squibb's Opdivo has been approved by the European Commission for use in a perioperative treatment regimen for high-risk resectable non-small cell lung cancer (NSCLC) patients, marking it as the first PD-(L)1 inhibitor approved for this indication in the EU [4] Capital Markets - Jiuzhoutong announced a participation in establishing a 25 million yuan industry fund, with a significant contribution of 22.99 million yuan, indicating a strategic move to foster innovation in pharmaceuticals and digital healthcare [5] - AbbVie has entered a collaboration with ADARx Pharmaceuticals to develop small interfering RNA (siRNA) therapies across multiple disease areas, with an upfront payment of $335 million and potential milestone payments totaling billions [6][7] Corporate Changes - Bluefan Medical announced a change in its indirect controlling shareholder, with Langhui Petrochemical acquiring a 52.0395% stake in Bluefan Investment, although the actual controller remains unchanged [8] - ST Muyu will remove risk warnings and change its name to Tianmu Pharmaceutical starting May 20, 2025, with an increase in daily price fluctuation limits from 5% to 10% [9] Industry Events - WuXi AppTec's investee company Hanbang Technology was listed on the Shanghai Stock Exchange on May 16, 2025, with WuXi holding 6.04% of the total shares post-IPO [10] Market Sentiment - Jinhe Biology's controlling shareholder plans to reduce its stake by up to 3% of the total shares, primarily to repay pledged debts [11] - ABA-Bio has completed a reduction of its stake in Yifang Bio by 9.23 million shares, representing 1.60% of the total shares [12]

益方生物科技（上海）股份有限公司 股东减持股份结果公告 证券代码：688382 证券简称：益方生物 公告编号：2025-021 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 公司于近日收到股东 ABA-Bio 出具的《关于减持股份结果的告知函》，现 将相关减持结果公告如下： | 股东名称 | ABA-Bio | | | | --- | --- | --- | --- | | | 控股股东、实控人及一致行动人 | □是 | √否 | | 股东身份 | 直接持股 5%以上股东 | √是 | □否 | | | 董事、监事和高级管理人员 | □是 | √否 | 一、减持主体减持前基本情况 1 大股东持有的基本情况：本次减持计划实施前，益方生物科技（上海）股份 有限公司（以下简称"公司"）股东 ABA-Bio（Hong Kong）Limited（以下 简称"ABA-Bio"）持有公司股份 32,940,037 股，占公司总股本的 5.70%。 股东持有的股份为 IPO 前取得。 减持计划的实施结果情况： ...

Core Insights - The pharmaceutical and biotechnology sector in A-shares has revealed significant disparities in employee compensation, with innovative drug companies dominating the highest salary rankings [1][2] Group 1: Highest Employee Compensation - The top ten companies in the pharmaceutical and biotechnology sector for employee compensation in 2024 are primarily innovative drug firms, with BeiGene (百济神州) leading at an average salary of 905,000 yuan [1][2] - Other companies in the top ten include Dizhihua Pharmaceutical (迪哲医药) with 686,700 yuan, Yahui Pharmaceutical (亚虹医药) with 627,400 yuan, and others, with salaries ranging from 480,600 yuan to 905,000 yuan [1][2] Group 2: R&D Personnel Impact - Innovative drug companies have a high proportion of R&D personnel, which contributes to elevated overall salary levels; BeiGene employs approximately 11,100 staff, with 3,905 in R&D, making up about 35% of the workforce [2] - The average salary for R&D personnel at BeiGene is 956,000 yuan, with domestic R&D staff earning 592,000 yuan and international R&D staff earning 1,586,000 yuan [2] Group 3: Lowest Employee Compensation - In contrast, the lowest ten companies in the sector have an average salary as low as 70,500 yuan, with a significant representation from traditional Chinese medicine firms [5][6] - The lowest salaries are reported for companies like Yisheng Pharmaceutical (益盛药业) at 70,500 yuan and others, with the majority of these companies experiencing declines in net profit [5][6] Group 4: Performance Trends - Among the top ten companies, eight have seen an increase in average salaries compared to 2023, with the highest increase at 13.62% for Ailisi (艾力斯) [4] - Ailisi's revenue reached 3.558 billion yuan in 2024, marking a 76.29% increase, while net profit rose by 121.97% to 1.43 billion yuan [4] Group 5: Challenges in the Sector - Companies like Te Yi Pharmaceutical (特一药业) have faced significant challenges, with a 91.9% decline in net profit attributed to changes in marketing strategies and reduced sales of key products [6][7] - The retail pharmacy sector is experiencing a downturn, with companies like Yixin Hall (一心堂) and Shuyuan Pingmin (漱玉平民) reporting over 69% declines in net profit due to increased competition and changes in consumer purchasing behavior [7][8]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return that will outperform the market benchmark by more than 15% over the next 6-12 months [5][12]. Core Insights - The company achieved a revenue of 169 million yuan in 2024, a decrease of 9.02% year-on-year, with a net loss attributable to the parent company of 240 million yuan [1][3]. - The successful approval of Gsorese tablets in November 2024 marks a significant milestone, alongside positive results from the D-2570 Phase II clinical trial for psoriasis [2][3]. - The company is advancing its clinical research with multiple products in various stages, including D-0502 in Phase III trials and D-0120 in Phase II trials [2]. Financial Summary - Revenue projections show a recovery with expected growth rates of 36.80% in 2025 and 35.89% in 2026, reaching 231 million yuan and 314 million yuan respectively [4][8]. - The net profit forecast for 2025 and 2026 has been revised down to -257 million yuan and -223 million yuan, respectively, with a new estimate for 2027 at -46 million yuan [3][4]. - The company’s total assets are projected to decline from 2,162 million yuan in 2023 to 1,438 million yuan by 2027, while total liabilities are expected to increase slightly [9]. Clinical Development Progress - The D-2570 product is being developed for multiple indications, including psoriasis, ulcerative colitis, and Crohn's disease, with promising clinical results indicating significant efficacy compared to existing treatments [2][3]. - The company has two products already authorized for sale and several others in various stages of clinical trials, showcasing a robust pipeline [2]. Market Performance - The current stock price is 22.56 yuan, with a market capitalization of approximately 13.047 billion yuan [5]. - The stock has shown a relative performance increase of 129.75% over the past year, indicating strong market interest [7].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688382 证券简称：益方生物 公告编号：2025-020 益方生物科技（上海）股份有限公司 关于股东权益变动的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 ■ （二）本次权益变动情况 重要内容提示： ● 本次权益变动属于益方生物科技（上海）股份有限公司（以下简称"公司"）持股5%以上股东履行此 前已披露的减持股份计划以及股权激励归属导致的被动稀释，不触及要约收购。 ● 本次权益变动后，公司股东ABA-Bio（Hong Kong）Limited（以下简称"ABA-Bio"）合计持有公司股 份28,916,393股，持股比例变动至5.00%。 ● 本次权益变动不会导致公司控股股东、实际控制人发生变化。 近日，公司收到股东ABA-Bio的书面通知，现将本次权益变动情况公告如下： 一、本次权益变动基本情况 （一）信息披露义务人基本信息 2025年4月29日，ABA-Bio通过集中竞价方式合计转让公司股份4,023,644股，持股比例由5.73% ...